Recombinant Human T-lymphocyte activation antigen CD86 (CD86)

What is CD86 and what are its primary functions in immune regulation?

Recombinant Human T-Lymphocyte Activation Antigen CD86 (also known as B7-2) is a costimulatory molecule expressed primarily on antigen-presenting cells. It provides essential secondary signals for T-lymphocyte activation by binding to either CD28 or CTLA-4 on T cells . This interaction is critical during the early stages of T-cell activation, particularly within the first 24 hours post-activation when the decision between immunity and anergy is determined . CD86 also regulates B cell function and influences IgG1 production levels .

The functional importance of CD86 extends beyond T cell activation. Upon CD40 engagement, CD86 activates the NF-kappa-B signaling pathway through phospholipase C and protein kinase C activation, contributing to broader immune response modulation . Research has demonstrated that CD86 plays differential roles in systemic and mucosal immune responses, with particularly important functions in mediating mucosal IgA responses .

How does CD86 differ from CD80 in immune regulation?

Despite sharing the same binding partners (CD28 and CTLA-4), CD86 and CD80 exhibit significant functional differences:

• Differential regulation of regulatory T cells (Tregs): CD86 and CD80 have opposing effects on Treg function. Blocking CD86 with antibodies enhances suppression by CD4+CD25+ Tregs, while blocking CD80 impairs Treg suppression and enhances proliferative responses .

• Expression patterns: CD80 and CD86 follow distinct expression dynamics during dendritic cell (DC) maturation. Immature DCs express substantial CD80 with lower CD86 levels, whereas mature DCs significantly upregulate CD86 expression, alongside CD83, CD40, and MHC class II molecules .

• T cell subset regulation: CD80 influences both Th1 and Th2-like IgG subclass responses, while CD86 preferentially influences Th2-associated IgG subclass responses to antigens .

• Memory vs. naive T cell responses: CD86 is substantially inferior in costimulating alloresponses by memory T cells compared to naive T cells, and completely incompetent in costimulating certain human T cell clones .

These differences suggest that CD80 and CD86 are not merely redundant costimulatory molecules but have evolved to provide distinct immunoregulatory signals.

What experimental models are most suitable for investigating CD86 function?

The choice of experimental model depends on the specific aspect of CD86 function being investigated:

• For studying CD86 effects on T cell activation: In vitro systems using CD86-transfected cell lines as antigen-presenting cells provide a controlled environment for examining direct CD86-mediated effects on T cell proliferation and cytokine production . When evaluating the differential effects of CD80 and CD86, CD80/CD86 double transfectants compared to single transfectants provide valuable insights .

• For studying CD86 in mucosal immunity: Intranasal immunization models using CD86 knockout mice (CD86−/−) are effective for examining the role of CD86 in mucosal IgA responses. These models have revealed CD86's unique importance in mediating mucosal responses following intranasal immunization .

• For studying CD86 in regulatory T cell function: Allostimulation assays using cultured dendritic cells with T cells in the presence of blocking antibodies against CD80 or CD86 allow examination of their differential effects on Treg suppression .

• For investigating CD86 in NK cell function: In vitro cytotoxicity assays using NK cell lines that constitutively express CD86 (such as NK-92MI cells) as effector cells against tumor target cells (like K562) can determine CD86's role in NK cell activation .

Each model system offers distinct advantages but may yield different outcomes, which partly explains apparently conflicting results in CD86 research .

How does CD86 expression impact immunotherapy efficacy and what methodologies are used to study this relationship?

CD86 expression has significant implications for immunotherapy efficacy, particularly for immune checkpoint blockers (ICBs). Research methodologies to investigate this relationship include:

• Correlation analysis between CD86 expression and response to immune checkpoint inhibitors: Using transcriptomic data from patient cohorts to correlate CD86 expression levels with clinical outcomes following immunotherapy .

• Comprehensive immune infiltration analysis: Multiple computational methods (CIBERSORT, MCPcounter, TIMER, Quantiseq, and Xcell) can be used to examine the relationship between CD86 expression and tumor-infiltrating immune cells. Studies have shown that high CD86 expression correlates with higher immune scores for 24 types of immune cells, suggesting enhanced immune infiltration .

• Differential gene expression analysis: The R package 'limma' can be used to analyze differences in expression of chemokines, immunostimulators, MHC proteins, and immune receptors based on high versus low CD86 expression, providing insights into how CD86 shapes the tumor immune microenvironment .

• Development of immune risk score models: These models incorporate CD86 expression and related immune markers to predict immunotherapy response, with validation against established metrics such as TIDE scores .

When designing studies to investigate CD86's role in immunotherapy, researchers should consider both direct CD86-mediated effects on T cell activation and broader effects on the tumor immune microenvironment.

What are the molecular mechanisms underlying the differential effects of CD86 on naive versus memory T cells?

The differential effects of CD86 on naive versus memory T cells involve complex molecular mechanisms:

• Receptor expression patterns: Memory T cells express higher baseline levels of CTLA-4 compared to naive T cells. Since CD86 has a higher affinity for CTLA-4 than for CD28, the dominance of CTLA-4 ligation may explain why CD86 is less effective at costimulating memory T cells .

• Signal transduction pathways: In activated T cells, CD86 engagement may preferentially activate inhibitory signaling pathways through CTLA-4. This is evidenced by experiments where addition of anti-CTLA-4 Fab to cultures of HLA-DR1 transfectants co-expressing CD86 fully restored proliferative responses .

• Temporal dynamics of costimulation: Naive T cells require stronger and more sustained costimulation compared to memory T cells. CD86's particular kinetics of engagement with CD28 versus CTLA-4 may be better suited to the costimulatory needs of naive T cells .

To study these mechanisms, researchers should employ:

• Flow cytometric analysis to quantify CD28 and CTLA-4 expression on different T cell subsets

• Signaling pathway analysis using phospho-specific antibodies to detect activation of distinct downstream pathways

• Temporal analysis of CD86 binding to CD28 versus CTLA-4 using live-cell imaging techniques

How can the contradictory outcomes of CD86 signaling in different experimental systems be reconciled?

The literature contains apparently conflicting results regarding CD86 function. These contradictions can be reconciled through several methodological approaches:

• Cell type-specific analysis: CD86 may have fundamentally different functions depending on the cell type expressing it. For example, CD86 on dendritic cells primarily influences T cell activation, while CD86 on NK cells enhances their cytotoxicity against tumor cells . Detailed phenotyping of cells expressing CD86 is crucial.

• Context-dependent signaling analysis: The outcome of CD86 signaling depends on the presence and relative expression of its binding partners. In systems where CTLA-4 expression is high, CD86 may deliver predominantly inhibitory signals, whereas in systems where CD28 predominates, CD86 may be stimulatory . Researchers should quantify the relative expression of CD28 and CTLA-4 on target cells.

• Maturation state considerations: The relative expression levels of CD80 and CD86 on dendritic cells change dramatically during progression from immature to mature states, correlating with their ability to support Treg suppression . Precise characterization of the maturation state is essential when interpreting results.

• Competitive binding experiments: To determine whether CD86 is functioning primarily through CD28 or CTLA-4 in a given system, researchers can use:

  • Anti-CD86 antibodies to compete with CTLA4Ig for binding to CD86

  • Temporal competition experiments where anti-CD86 antibody is added before or simultaneously with CTLA4Ig

As noted in the literature, "The conflicting results and contradictory outcomes may reflect the different model systems and readouts used" .

What methods are most effective for analyzing CD86-mediated changes in immune cell subsets?

Effective analysis of CD86-mediated changes in immune cell subsets requires a combination of techniques:

• Flow cytometry-based approaches:

  • Multiparameter flow cytometry to simultaneously assess changes in multiple immune cell populations

  • Intracellular cytokine staining to determine functional changes in T cell subsets following CD86 engagement

  • Phospho-flow cytometry to examine activation of signaling pathways downstream of CD86 interactions

• Gene expression profiling:

  • Single-cell RNA sequencing to characterize heterogeneity in responses to CD86 signaling

  • Bulk RNA sequencing with differential expression analysis using the 'limma' package to identify CD86-regulated genes

  • GSEA (Gene Set Enrichment Analysis) to identify pathways modulated by CD86 signaling

• Functional assays:

  • Suppression assays to measure CD86 effects on Treg function

  • Cytotoxicity assays to assess CD86 influence on NK cell killing capacity

  • Enzyme-linked immunospot (ELISPOT) assays to measure cytokine production at the single-cell level

• In vivo tracking:

  • Adoptive transfer experiments using CD86-deficient cells or wild-type cells treated with anti-CD86 antibodies

  • In vivo imaging to track cellular interactions following CD86 modulation

The choice of methods should be guided by the specific research question, with consideration given to the limitations of each approach.

How does CD86 expression on NK cells influence anti-tumor immunity and what experimental approaches best demonstrate this function?

CD86 expression on NK cells has emerged as an important factor in anti-tumor immunity, with distinct functional implications from its role on antigen-presenting cells:

• Expression patterns: Approximately 6% of NK cells express CD86, but fewer than 1% express CD80 . This expression increases following encounter with tumor cells, as demonstrated when NK cells were cultured with YAC-1 cells or isolated from lungs of mice inoculated with B16 melanoma cells .

• Functional significance: CD86 acts as an activation receptor for NK cell cytotoxicity against tumor cells. This was demonstrated using NK-92MI cells that constitutively express CD86 (>70.6%) as effector cells in cytotoxicity assays .

• Mechanistic investigation: The role of CD86 in NK cell activation was confirmed through competition experiments where:

  • Anti-CD86 antibody partially blocked CTLA4Ig-mediated enhancement of NK cell cytotoxicity when added simultaneously

  • Anti-CD86 antibody completely abolished CTLA4Ig-mediated NK cell activation when added 2 hours earlier

Experimental approaches to study CD86 on NK cells include:

• Cytotoxicity assays:

  • 51Cr-release assays or flow cytometry-based killing assays with NK cells expressing or lacking CD86

  • Inclusion of blocking antibodies or CTLA4Ig to modulate CD86 signaling

• In vivo tumor models:

  • B16 melanoma lung metastasis model to assess NK cell infiltration and CD86 expression

  • Adoptive transfer of CD86-deficient versus wild-type NK cells to assess tumor control

• Signaling pathway analysis:

  • Western blotting or phospho-flow to identify signaling events downstream of CD86 engagement

  • Chemical inhibitors to block specific pathways and determine their importance for CD86-mediated NK activation

These approaches collectively demonstrate that "CD86 rather than CD80 on NK cells was involved in the enhancement of NK cell cytotoxicity to tumors" .

How can CD86 expression be leveraged as a biomarker for immunotherapy response?

CD86 expression has significant potential as a biomarker for immunotherapy response based on its association with immune infiltration and immunotherapy efficacy:

• Development of predictive models:

  • Integration of CD86 expression with other immune markers to create immune risk score (IRS) models

  • Validation of these models using independent datasets to confirm predictive value

  • Comparison with established predictors such as TIDE scores

• Multi-omics approaches:

  • Correlation of CD86 expression with mononucleotide variation, gene copy number variation, and methylation patterns

  • Analysis of the relationship between CD86 expression and T-cell inflammation scores

  • Integration of these data to create comprehensive predictive algorithms

• Tissue-specific considerations:

  • Assessment of CD86 expression in tumor tissue versus peripheral blood

  • Analysis of CD86 expression on specific cell types within the tumor microenvironment

  • Correlation of site-specific CD86 expression with response to different immunotherapy modalities

• Methodological approaches:

  • Immunohistochemistry for tissue samples

  • Flow cytometry for blood and dissociated tissue samples

  • RNA sequencing or NanoString technology for gene expression profiling

Research has shown that high CD86 expression correlates with increased immune infiltration across multiple immune cell types, suggesting its potential value as part of a comprehensive biomarker panel for immunotherapy response prediction .

What are the key methodological considerations when using recombinant CD86 protein in experimental systems?

When using recombinant CD86 protein in experimental systems, several methodological considerations are critical:

• Protein quality and activity:

  • Purity: Ensure greater than 95% purity as determined by SDS-PAGE to avoid confounding effects from contaminants

  • Endotoxin levels: Use preparations with less than 1.0 EU/μg as determined by LAL method to prevent non-specific immune activation

  • Biological activity: Verify functional activity through binding assays, such as the ability to bind Human CTLA-4 in functional ELISA (ED50 less than 20 μg/ml)

• Expression system considerations:

  • Human CD86 protein expressed in mammalian cell systems is preferred for studies involving human immune cells to ensure proper glycosylation and folding

  • The expression range (e.g., amino acids 24-247) should be selected to include the extracellular domain responsible for receptor binding

• Buffer and storage conditions:

  • Use protein reconstituted in physiologically relevant buffers (e.g., 20 mM PB, 150 mM NaCl, pH 7.2)

  • Aliquot the protein upon receipt and store at -20°C/-80°C to avoid repeated freeze-thaw cycles

  • Perform stability testing to ensure the protein maintains activity throughout experimental timeframes

• Experimental design factors:

  • Include appropriate controls (inactive protein, isotype controls)

  • Determine optimal concentration ranges through dose-response experiments

  • Consider the timing of CD86 addition relative to other stimuli based on its role in early T cell activation

• Functional readouts:

  • T cell proliferation assays

  • Cytokine production analysis

  • Signaling pathway activation assessment

Following these methodological considerations ensures reliable and reproducible results when using recombinant CD86 protein in research applications.

What are the emerging questions regarding CD86's role in non-classical immune cells and tissues?

While CD86's function on antigen-presenting cells is well-established, several emerging questions address its role in non-classical immune contexts:

• CD86 on NK cells:

  • What is the transcriptional program governing CD86 expression on NK cells?

  • How does CD86-mediated activation of NK cells differ mechanistically from classical NK activating receptors?

  • Can CD86+ NK cells be selectively expanded for cancer immunotherapy?

• CD86 in mucosal immunity:

  • What factors determine CD86's unique importance in mucosal versus systemic immune responses?

  • How does CD86 expression on mucosal dendritic cells respond to different adjuvants (e.g., CTB versus MPL)?

  • What is the role of CD86 in maintaining mucosal tolerance versus immunity?

• Tissue-resident CD86 expression:

  • Which non-immune cells express CD86 in different tissue contexts?

  • What is the functional significance of CD86 expression on tissue-resident cells?

  • How does tissue-specific regulation of CD86 contribute to local immune responses?

• Methodological approaches for these questions:

  • Single-cell RNA sequencing to identify novel CD86-expressing cell populations

  • Tissue-specific conditional knockout models to assess CD86 function in defined contexts

  • Advanced imaging techniques to visualize CD86-mediated cellular interactions in situ

These emerging questions represent important frontiers in understanding CD86 biology beyond its classical role in T cell costimulation.

How can computational and systems biology approaches advance our understanding of CD86 network interactions?

Computational and systems biology approaches offer powerful tools for understanding complex CD86 network interactions:

• Network analysis methods:

  • Protein-protein interaction (PPI) network analysis using STRING and visualization with Cytoscape

  • Identification of critical clusters using the MCODE plug-in

  • Integration of CD86-associated differentially expressed genes (DEGs) with stromal and immune scores

• Pathway enrichment analysis:

  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis to identify biological processes and pathways associated with CD86 expression

  • Filtering based on significance thresholds (|Log2FC| ≥ 1 and FDR < 0.05)

• Multivariate data integration:

  • Correlation of CD86 expression with:

    • Chemokine expression

    • Immunostimulator levels

    • MHC protein expression

    • Immune receptor profiles

• Machine learning approaches:

  • Development of predictive models for CD86-associated immune phenotypes

  • Feature selection to identify key genes co-regulated with CD86

  • Validation across multiple datasets to ensure robustness

• Visualization techniques:

  • Heat maps and volcano plots to represent CD86-associated DEGs

  • Network visualization to identify hub genes and critical interactions

  • Cellular interaction maps based on CD86 expression patterns

These computational approaches can help reconcile seemingly contradictory experimental findings by identifying context-dependent regulatory networks and revealing how CD86 functions within larger immunological systems.